期刊
MOLECULAR THERAPY
卷 30, 期 1, 页码 295-310出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2021.08.009
关键词
-
资金
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine
- Office of the Director of National Institutes of Health (NIH) [T32OD011130]
- Division of Intramural Research of NIAID within the National Institutes of Health
This study developed an innovative approach using chemically stable exon skipping oligonucleotides (ESOs) to target KIT expression, which resulted in downregulation of KIT, inhibition of MC proliferation, and induction of apoptosis in neoplastic cells. In vivo administration of KIT targeting ESOs significantly inhibited tumor growth and organ infiltration, suggesting its potential as a therapeutic strategy for KIT-associated malignancies.
Activating mutations in c-KIT are associated with the mast cell (MC) clonal disorders cutaneous mastocytosis and systemic mastocytosis and its variants, including aggressive systemic mastocytosis, MC leukemia, and MC sarcoma. Currently, therapies inhibiting KIT signaling are a leading strategy to treat MC proliferative disorders. However, these approaches may have off-target effects, and in some patients, complete remission or improved survival time cannot be achieved. These limitations led us to develop an approach using chemically stable exon skipping oligonucleotides (ESOs) that induce exon skipping of precursor (pre-)mRNA to alter gene splicing and introduce a frameshift into mature KIT mRNA transcripts. The result of this alternate approach results in marked downregulation of KIT expression, diminished KIT signaling, inhibition of MC proliferation, and rapid induction of apoptosis in neoplastic HMC-1.2 MCs. We demonstrate that in vivo administration of KIT targeting ESOs significantly inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft MC tumor model. We propose that our innovative approach, which employs well-tolerated, chemically stable oligonucleotides to target KIT expression through unconventional pathways, has potential as a KIT-targeted therapeutic alone, or in combination with agents that target KIT signaling, in the treatment of KIT-associated malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据